ANNOUNCEMENT OF APPLICATION FOR ADMISSION TO THE AQUIS GROWTH MARKET |
|
APPLICANT NAME: |
Blackpoint Biotech plc |
APPLICANT REGISTERED OFFICE, PRINCIPLE PLACE OF BUSINESS (IF DIFFERENT) AND TELEPHONE NUMBER: |
48-49 Chancery Lane, C/O Keystone Law, London, England, WC2A 1JF +44 208 050 6458 |
DIRECTORS AND PROPOSED DIRECTORS (IF APPLICABLE): |
- Michael William Balfour, Non-Executive Chairman
- David Manuel Martinez, Chief Executive Officer
- Alexander James Robert Stormont Wakeford, Chief Financial Officer
- Dr Michael Barry Mayne, Chief Product Officer
|
APPLICANT SECTOR: |
Healthcare |
DESCRIPTION OF THE APPLICANT AND ITS ACTIVITIES: |
Blackpoint Biotech PLC is a medical cannabinoids company established to fulfil gaps in the medical cannabis market by creating products that provide fast onset of action and accurate dosing. |
NAME OF AQSE CORPORATE ADVISER: |
First Sentinel Corporate Finance Limited |
NUMBER, CLASS AND PAR VALUE OF SECURITIES TO BE ADMITTED: |
12,187,179 Ordinary Shares of £0.005 each |
SECURITIES IN PUBLIC HANDS AS A PERCENTAGE OF THE TOTAL NUMBER OF SECURITIES IN ISSUE (excluding securities held in treasury): |
15.12% |
SHAREHOLDERS HOLDING MORE THAN FIVE PER CENT OF THE APPLICANT’S SHARE CAPITAL OR VOTING RIGHTS PRE- AND POST-ADMISSION: |
Shareholder | Shares Pre-admission | % Pre-admission | Shares Post-admission | % Post-admission | David Martinez | 4,078,102 | 33.46% | 4,078,102 | 33.46% | Alexander Wakeford | 1,581,696 | 12.98% | 1,581,696 | 12.98% | Michael Mayne | 2,105,000 | 17.27% | 2,105,000 | 17.27% | Creedy Carver Chickens Limited | 2,271,410 | 18.64% | 2,271,410 | 18.64% |
|
TIMETABLE FOR ANY OFFER OF TRANSFERABLE SECURITIES TO THE PUBLIC: |
N/A |
THE EXPECTED ADMISSION DATE: |
TBD The company has applied to Euroclear to have the shares enabled in CREST and the process has not yet been concluded. |
WEBSITE ADDRESS WHERE INVESTOR INFORMATION WILL BE AVAILABLE FOR INSPECTION: |
www.blackpointbiotech.com |
In respect of an update to a prior application announcement, the date of the original announcement should also be disclosed as follows: |
UPDATE TO A PRIOR APPLICATION ANNOUNCEMENT RELEASED ON: |
06 July 2023 |
